entially for the identiﬁcation of patients at high VTE
risk in whom the beneﬁt of receiving chemical chemoprophylaxis outweighs the attendant bleeding risk. A
widely accepted risk threshold is a calculated VTE risk
of 3%, assuming a two-fold reduction in VTE events
compared with expected bleeding events from administration of an anticoagulant.241 Currently, no VTE risk
assessment model (RAM) has been validated in patients
